Financials · IBIO

iBio Inc. (IBIO) financials

For the twelve months ended Sep 30, 2026, iBio Inc. reported $1.07M of revenue and -$34.88M of net income.

Revenue, TTM
$1.07M
Revenue growth, YoY
+115.0%
Net income, TTM
-$34.88M
Net margin
-3244.2%
Free cash flow, TTM
-$27.59M
Cash
$45.44M
P/S
47.98
Market cap
$51.6M
Annual revenue$100.0K
FY2017FY2026
Annual net income-$33.04M
FY2017FY2026
Annual free cash flow-$23.80M
FY2017FY2026

IBIO revenue and earnings growth

IBIO revenueQ1 2027$1.07M

Quarter YoY
+975.0%
FY YoY
-75.0%
5Y CAGR
-46.9%
10Y CAGR
-20.1%

IBIO revenue was $1.07M in fiscal Q1 2027 (ended Sep 30, 2026), up 975.0% from a year earlier. For the full fiscal 2026 it was $100.0K, down 75.0% from fiscal 2025. Compound annual growth was -46.9% over 5 years and -20.1% over 10 years.

IBIO net incomeQ1 2027-$7.55M

IBIO net income was -$7.55M in fiscal Q1 2027 (ended Sep 30, 2026), compared with -$5.72M a year earlier. For the full fiscal 2026 it was -$33.04M, compared with -$18.38M in fiscal 2025.

IBIO EPSQ1 2027-$0.05

IBIO diluted EPS was -$0.05 in fiscal Q1 2027 (ended Sep 30, 2026). For the full fiscal 2026 it was -$0.32.

IBIO free cash flowQ1 2027-$9.49M

IBIO free cash flow was -$9.49M in fiscal Q1 2027 (ended Sep 30, 2026), compared with -$5.70M a year earlier. For the full fiscal 2026 it was -$23.80M, compared with -$15.32M in fiscal 2025.

Export CSV

Income statement

Income statement
Line item
Jun 30, 2026
Jun 30, 2025
Jun 30, 2024
Jun 30, 2023
Jun 30, 2022
Jun 30, 2021
Jun 30, 2020
Jun 30, 2019
Jun 30, 2018
Jun 30, 2017
Revenue$100.0K$400.0K$225.0K$0$1.88M$2.37M$1.64M$2.02M$444.0K$394.0K
Cost of revenue----$216.0K$1.46M$703.0K---
Gross profit----$2.17M$909.0K$935.0K---
Research and development$19.64M$8.31M$5.18M$10.33M$9.83M$9.99M$3.57M$5.47M$3.99M$4.12M
Selling, general and admin$10.60M$10.69M$11.67M$19.02M$21.75M$22.03M$11.37M$12.33M$10.69M$10.55M
Operating income-$35.14M-$18.60M-$16.63M-$29.34M-$29.70M-$31.11M-$14.00M-$15.79M-$14.23M-$14.27M
Interest expense$53.0K$212.0K$172.0K$83.0K$1.41M$2.45M$2.47M$1.90M$1.92M$1.93M
Pre-tax income-$33.04M-$18.38M--------
Income tax$0$0$0$0$0$0$0$0$0$0
Net income-$33.04M-$18.38M-$24.91M-$65.01M-$29.60M-$23.21M-$16.44M-$17.59M-$16.11M-$14.53M
EPS, basic-$0.32-$1.75-$6.50-$106.19-$115.60-$60.00-$12.20-$18.80-$30.80-$32.80
EPS, diluted-$0.32-$1.75-$6.50-$106.19-$115.60-$60.00-$12.20-$18.80-$30.80-$32.80
Diluted shares104.1M10.5M3.8M612,000436,050391,2503.1M946,300531,550445,550

Balance sheet

Balance sheet
Line item
Jun 30, 2026
Jun 30, 2025
Jun 30, 2024
Jun 30, 2023
Jun 30, 2022
Jun 30, 2021
Jun 30, 2020
Jun 30, 2019
Jun 30, 2018
Jun 30, 2017
Cash and equivalents$56.40M$8.79M$14.43M$7.58M$28.67M$77.40M$55.11M$4.42M$4.42M$15.93M
Receivables-$0$0$0$1.00M$426.0K$75.0K$97.0K$75.0K$175.0K
Inventory--$0$0$3.90M$27.0K----
Current assets$92.22M$9.72M$15.67M$26.26M$45.07M$104.60M$61.75M$4.81M$16.29M$8.57M
Total assets$99.11M$23.18M$28.73M$41.21M$99.41M$146.97M$94.19M$30.59M$43.08M$36.01M
Current liabilities$11.74M$6.11M$3.84M$22.11M$30.44M$6.64M$5.24M$3.46M$2.04M$2.01M
Total liabilities$13.40M$8.30M$7.41M$25.83M$35.92M$38.40M$37.58M$28.13M$26.92M$27.09M
Shareholders' equity$85.71M$14.88M$21.32M$15.38M$63.48M$108.57M$56.61M$2.46M$16.16M$8.91M

Cash flow

Cash flow
Line item
Jun 30, 2026
Jun 30, 2025
Jun 30, 2024
Jun 30, 2023
Jun 30, 2022
Jun 30, 2021
Jun 30, 2020
Jun 30, 2019
Jun 30, 2018
Jun 30, 2017
Operating cash flow-$23.22M-$15.30M-$18.55M-$30.44M-$37.48M-$30.06M-$13.35M-$13.97M-$13.48M-$13.16M
Capital expenditures$578.0K$16.0K$210.0K$5.74M$7.33M$4.92M$1.08M$920.0K$934.0K$1.32M
Free cash flow-$23.80M-$15.32M-$18.76M-$36.17M-$44.81M-$34.98M-$14.42M-$14.89M-$14.41M-$14.49M
Investing cash flow-$32.00M$742.0K$906.0K$7.01M-$5.13M-$26.48M-$1.15M-$990.0K-$1.08M-$1.59M
Financing cash flow$103.05M$8.93M$24.49M$2.30M-$6.13M$78.83M$65.19M$3.45M$22.41M-$170.0K
Stock-based compensation$1.37M$1.53M$2.04M$4.39M$4.38M$1.59M$388.0K$241.0K$770.0K$1.01M
Depreciation and amortization-------$179.0K--

Key ratios

Key ratios
Line item
Jun 30, 2026
Jun 30, 2025
Jun 30, 2024
Jun 30, 2023
Jun 30, 2022
Jun 30, 2021
Jun 30, 2020
Jun 30, 2019
Jun 30, 2018
Jun 30, 2017
Revenue growth, YoY-75.0%77.8%--100.0%-20.5%44.7%-18.8%354.5%12.7%-58.4%
Gross margin----115.0%38.3%57.1%---
Operating margin-35141.0%-4650.5%-7392.9%--1576.3%-1312.1%-854.9%-782.4%-3204.3%-3622.8%
Net margin-33044.0%-4594.3%-11069.8%--1571.1%-978.8%-1003.6%-871.8%-3627.3%-3688.3%
Free cash flow margin-23796.0%-3830.0%-8339.6%--2378.5%-1475.5%-880.5%-738.1%-3246.4%-3676.6%
Return on equity-38.6%-123.5%-116.8%-422.7%-46.6%-21.4%-29.0%-716.0%-99.6%-163.0%
Return on assets-33.3%-79.3%-86.7%-157.8%-29.8%-15.8%-17.5%-57.5%-37.4%-40.4%
Current ratio7.851.594.081.191.4815.7411.791.398.004.26

Source: XBRL data iBio Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Sep 18, 2018; 1-for-20, first reported Feb 9, 2024.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

IBIO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
IBIO$1.07M+115.0%-$34.88M-3244.2%$51.6M
EBS$649.10M-17.7%-$260.70M-40.2%$297.7M

IBIO FAQ

7 questions
  • What is IBIO revenue?
    iBio Inc. (IBIO) reported $1.07M of revenue for the twelve months ended Sep 30, 2026. That is up 115.0% from the year before. Revenue for fiscal 2026 was $100.0K.
  • Is IBIO profitable?
    No. iBio Inc. reported a net loss of $34.88M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does IBIO have?
    iBio Inc. reported $45.44M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is IBIO revenue growing?
    iBio Inc.'s revenue changed -75.0% in fiscal 2026, to $100.0K. Its compound annual growth rate was -46.9% over 5 years and -20.1% over 10 years.
  • What is IBIO free cash flow?
    iBio Inc. generated -$27.59M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$26.94M less capital expenditures.
  • When did IBIO last report financial results?
    The latest statements here come from iBio Inc.'s 10-Q filed on Nov 10, 2026, covering the period ended Sep 30, 2026.
  • Where does this IBIO financial data come from?
    Quantisnow builds these statements from the structured XBRL data iBio Inc. files with the SEC. It is provided for information only and is not investment advice.